Regulus Therapeutics’ (RGLS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS) in a report released on Monday,Benzinga reports. HC Wainwright currently has a $10.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Regulus Therapeutics’ Q4 2024 earnings at ($0.22) EPS, FY2024 earnings at ($0.86) EPS, Q1 2025 earnings at ($0.23) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS and FY2025 earnings at ($0.95) EPS.

Other analysts also recently issued research reports about the stock. StockNews.com raised shares of Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th. Oppenheimer reiterated an “outperform” rating and set a $7.00 price objective on shares of Regulus Therapeutics in a research note on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Regulus Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $10.80.

Regulus Therapeutics Stock Performance

NASDAQ RGLS opened at $1.50 on Monday. The company has a market capitalization of $98.25 million, a price-to-earnings ratio of -1.40 and a beta of 1.63. Regulus Therapeutics has a one year low of $1.08 and a one year high of $3.79. The company’s 50-day simple moving average is $1.55 and its two-hundred day simple moving average is $1.81.

Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). Equities analysts expect that Regulus Therapeutics will post -0.83 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in Regulus Therapeutics by 158.4% in the 1st quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock worth $2,132,000 after purchasing an additional 453,784 shares during the period. Renaissance Technologies LLC grew its holdings in Regulus Therapeutics by 56.4% in the second quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 42,600 shares during the period. Creative Planning acquired a new position in shares of Regulus Therapeutics during the 3rd quarter worth approximately $26,000. Rhumbline Advisers acquired a new position in shares of Regulus Therapeutics during the 2nd quarter worth approximately $136,000. Finally, SG Americas Securities LLC acquired a new stake in Regulus Therapeutics in the 3rd quarter valued at $33,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.